Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MYGN -- Ignore unavailable to you. Want to Upgrade?

To: Roger Steiner who wrote (14)	4/9/1998 7:29:00 AM
From: Lee Allgood	Read Replies (2) \| Respond to of 29

Yes, and I am in for the long haul. This is an extremely undervalued biotech. See the April 6th issue of Forbes, page 134. With genetic testing AND the ProNet database (I believe that only Beyer is licsencing at this time; $3 million per 5 yr licsence with royalties to MYGN for drugs developed using technology), this company will takeoff over the next 12-18 months. Should be comparable in valuation to Incyte (again, see the Forbes article). I have spoken to IR and there will be other big pharma cos. licsening ProNet in the "near term". Near term was not defined, but I interpret it to mean before year end. Lee